Evercore ISI raised the firm’s price target on Crinetics (CRNX) to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as “very strong updates” on atumelnant in CAH and the Palsonify launch in acromegaly. The firm believes the atumelnant update will be “much more impactful” for the stock today as it contends that Crinetics “again looks to comfortably have 2 blockbuster,” high odds of success products and more in earlier development.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics reports Q4 PALSONIFY U.S. preliminary net product revenue of over $5M
- Crinetics announces ‘positive’ topline results from fourth cohort of CAH study
- Crinetics drops 9% after executive Dana Pizzuti steps down
- Crinetics doses first patient in CALM-CAH trial
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’